Drug Profile
Adenovirus-specific T cells - Allovir
Alternative Names: Adenovirus-specific T cell therapy - Allovir; AdV-specific T cell therapy - AlloVir; AdV-specific T cells - AlloVir; HLA-matched AdV-specific T cells - AlloVir; Human leukocyte antigen (HLA)-matched adenovirus-specific T lymphocytes - AlloVir; Viralym-ALatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator ViraCyte
- Developer AlloVir
- Class T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Adenovirus infections